<DOC>
	<DOCNO>NCT02372955</DOCNO>
	<brief_summary>Dapagliflozin show low clinic systolic diastolic blood pressure patient type 2 diabetes mellitus . The exact mechanism ( ) dapagliflozin lower clinic SBP unknown . The primary objective study determine effect dapagliflozin , 10 mg daily , parameter arterial stiffness : aPWV , augmentation index ( AI ) , 24-hour blood pressure pattern , SBP , pulse pressure . Urinary sodium excretion , Intravascular volume status record . The study involve 21 subject duration 16 week .</brief_summary>
	<brief_title>Mechanistic Study Systolic Blood Pressure Lowering Effect Dapagliflozin Type 2 Diabetes</brief_title>
	<detailed_description>Dapagliflozin show low clinic systolic diastolic blood pressure patient type 2 diabetes mellitus . In particular , reduction SBP impressive . The effect circadian pattern blood pressure measure ambulatory blood pressure monitoring establish . The exact mechanism ( ) dapagliflozin lower clinic SBP clear although speculation due decrease intravascular volume secondary osmotic diuresis produce drug . However , SBP dependent pulse volume vascular stiffness ( impedance ejection ) . Dapagliflozin may favorable effect vascular stiffness reduction blood glucose result decrease proximal arterial collagen cross-linking due non-enzymatic glycosylation protein . Dapagliflozin may also favorable effect vascular stiffness increase urinary sodium excretion . Dapagliflozin sodium/glucose co-transporter inhibitor effect sodium excretion clear . Increased sodium intake associate increase vascular stiffness . An increase vascular stiffness correlate increase cardiovascular morbidity mortality . Thus , important know dapagliflozin effect vascular stiffness . The current `` gold standard '' vascular stiffness aortic pulse wave velocity ( aPWV ) . Other measure vascular stiffness include : systolic blood pressure , pulse pressure augmentation index . Also , measurement calculate central blood pressure provide information may apparent measurement brachial blood pressure . Measures intravascular volume status include : body weight , jugular venous pressure , orthostatic change blood pressure heart rate . It important recognize oral anti-diabetic drug , e.g . sulfonylurea 's associated increase systemic arterial blood pressure . Hypothesis That treatment type 2 diabetes mellitus dapagliflozin result decrease arterial stiffness Primary Objectives The primary objective study determine effect dapagliflozin ( Appendix A ) , 10 mg daily , parameter arterial stiffness : aPWV , augmentation index ( AI ) , 24-hour blood pressure pattern , SBP , pulse pressure . Key Questions - What effect dapagliflozin measure arterial stiffness ? - What effect dapagliflozin central blood pressure ? - Will dapagliflozin low BP 24-hour period pattern BP change ? - Will dapagliflozin increase sodium excretion 16 week ? - What effect dapagliflozin intravascular volume status 16 week ? Secondary Objectives - Urinary sodium excretion - Intravascular volume status : jugular venous pressure , body weight , orthostatic change BP pulse rate Treatment All patient receive background treatment metformin . After randomization ( 2:1 ) patient receive dapagliflozin , 10 mg daily glimpiride ( Appendix B ) , 4 mg daily . The treatment period last ; 16 week . For high risk subject , dapagliflozin therapy begin 5 mg up-titration 2 week . High risk subject prone volume depletion identify sign hypovolemia , e.g . low venous pressure , low arteriasl blood pressure . Subjects also closely monitored development hypoglycemia . This risk minimize enrolling subject take insulin . Subjects make aware sign hypotlycemia , e.g . sweat palpitation , instruct treat ingestion sugar , particularly fructose orange juice .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 diabetes mellitus Metformin treatment â€¢ Type 1 diabetes mellitus Hgb A1c &gt; 9 Advanced diabetic complication , e.g . diabetic renal disease ( eGFR &lt; 60 cc/min ) , heavy proteinuria , diabetic retinopathy , autonomic neuropathy Pregnancy unwilling practice contraception . Uncontrolled hypertension ( SBP &gt; 150 mm Hg ; DBP &gt; 100 mm Hg ) Chronic substance abuser Carcinoma urinary bladder Subjects deem risk dehydration</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>